About Us

 
Owl Brain (1).png

Mission

Transform tissues into actionable insights to accelerate drug discovery through advanced imaging and digital image analysis.

How We Started

The inspiration for Visikol grew out of a plant microscopy class at Rutgers University in the fall of 2011. Visikol Chief Scientific Officer, Dr. Tom Villani, learned of the labor intensive process of obtaining and using the traditional plant clearing agent, chloral hydrate. As a highly regulated narcotic with a long history of abuse, chloral hydrate was far from an easily accessible or safe agent to use in biology research. Tom knew there had to be an easier way.

Working with an advisory team of Dr. Jim Simon and Dr. Adolfina Koroch, the original Visikol® tissue clearing technology was born in the labs at Rutgers University as a safe and easy-to-use tissue clearing agent for plant biology research. As we very quickly learned, the potential of this tissue clearing technology was not solely limited to plant biology. By working with the technology, we found new and unique ways to apply it to clear a wide range of biological tissues as well as techniques to obtain quantitative three-dimensional data from tissues. Today, we have expanded well beyond the world of plant biology and are excited to bring you a suite of tissue clearing reagents as well as a three-dimensional tissue imaging and quantitative analysis service offering. 

Where We are Today

We have transitioned from a company just selling reagents and kits for academic researchers to a full service contract research organization focused on digital pathology, 3D and 2D in vitro assays and advanced whole mount imaging. We partner closely with pharmaceutical companies on their drug discovery efforts and see ourselves as experts in developing customized solutions for complex research questions. 

 

Visikol Team

  DR. MICHAEL JOHNSON   Chief Executive Officer   Dr. Johnson leads the overall strategy for Visikol and is responsible on a day-to-day basis for business development and technology commercialization.    Contact Dr. Michael Johnson

DR. MICHAEL JOHNSON
Chief Executive Officer

Dr. Johnson leads the overall strategy for Visikol and is responsible on a day-to-day basis for business development and technology commercialization. 

Contact Dr. Michael Johnson

  DR. TOM VILLANI   Chief Science Officer   Dr. Villani is responsible for coupling R&D to business strategy at Visikol. Tom leads scientific research, product development, and academic collaborations for Visikol.   Contact Dr. Tom Villani

DR. TOM VILLANI
Chief Science Officer

Dr. Villani is responsible for coupling R&D to business strategy at Visikol. Tom leads scientific research, product development, and academic collaborations for Visikol.

Contact Dr. Tom Villani

  DR. GRAEME GARDNER   Director of Research   Dr. Gardner is focused on applying the Visikol HISTO technology to high-value applications in the drug discovery space. Graeme leads the day-to-day operation of the lab and the development of various Visikol HISTO technology applications.   Contact Dr. Graeme Gardner

DR. GRAEME GARDNER
Director of Research

Dr. Gardner is focused on applying the Visikol HISTO technology to high-value applications in the drug discovery space. Graeme leads the day-to-day operation of the lab and the development of various Visikol HISTO technology applications.

Contact Dr. Graeme Gardner

  BRIAN MULHALL   Director of Corporate Development   Brian was previously the Chief Operations Officer of Whitehouse Analytical Laboratories and now leads Visikol's partnering as well as business operations, governance and compliance.    

BRIAN MULHALL
Director of Corporate Development

Brian was previously the Chief Operations Officer of Whitehouse Analytical Laboratories and now leads Visikol's partnering as well as business operations, governance and compliance. 

 

 
  DR. ERIN EDWARDS   Director of In Vitro Studies   Dr. Edwards leads Visikol's 3D and 2D  in vitro  assay services and is responsible for developing best-in-class assays that leverage Visikol's 3Screen image analysis algorithms and high content confocal imaging.   Contact Dr. Erin Edwards

DR. ERIN EDWARDS
Director of In Vitro Studies

Dr. Edwards leads Visikol's 3D and 2D in vitro assay services and is responsible for developing best-in-class assays that leverage Visikol's 3Screen image analysis algorithms and high content confocal imaging.

Contact Dr. Erin Edwards

  ALEX MAGSAM   Imaging Scientist   Alex is focused on developing best-in-class 3D imaging and analysis algorithms for Visikol's 3Screen services. Additionally, Alex has led the development of Visikol's Clara optical CT scanner. 

ALEX MAGSAM
Imaging Scientist

Alex is focused on developing best-in-class 3D imaging and analysis algorithms for Visikol's 3Screen services. Additionally, Alex has led the development of Visikol's Clara optical CT scanner. 

  DR. ADAM KUEHN   Pathologist   Dr. Kuehn is a fellowship trained anatomical pathologist that leads Visikol's traditional histopathology services associated with its digital pathology portfolio of services. 

DR. ADAM KUEHN
Pathologist

Dr. Kuehn is a fellowship trained anatomical pathologist that leads Visikol's traditional histopathology services associated with its digital pathology portfolio of services.